Abstract
MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Current Chemical Biology
Title:MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Volume: 6 Issue: 1
Author(s): Miao Ming, Xu Zhao, Zi-yi Zhao, Bo Liu and Jin-ku Bao
Affiliation:
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Abstract: MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Export Options
About this article
Cite this article as:
Ming Miao, Zhao Xu, Zhao Zi-yi, Liu Bo and Bao Jin-ku, MicroRNA Regulation of Programmed Cell Death Pathways in Cancer, Current Chemical Biology 2012; 6 (1) . https://dx.doi.org/10.2174/2212796811206010053
DOI https://dx.doi.org/10.2174/2212796811206010053 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease
Current Molecular Medicine Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Towards Liver-Directed Gene Therapy for Crigler-Najjar Syndrome
Current Gene Therapy Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Anti-Cancer Agents in Medicinal Chemistry Safety Concerns Related to Hematopoietic Stem Cell Gene Transfer Using Retroviral Vectors
Current Gene Therapy Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued)